We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca-Amgen Drug Gets FDA Priority Review as Asthma Treatment
AstraZeneca-Amgen Drug Gets FDA Priority Review as Asthma Treatment
The FDA has granted a Priority Review to AstraZeneca and Amgen’s investigational asthma treatment tezepelumab — setting a target decision date for the Biologics License Application (BLA) in the first quarter of 2022.